FIBRASIC 2009.

Methods	Design: open‐label RCT Duration: not reported Follow up: 12 months
Participants	Setting: multicentre (4 centres) Country: Belgium De novo Kidney transplant recipients Number (group 1/group 2): 45 (24/21) Mean age ± SD (years): not reported Sex (M/F): not reported Exclusions: not reported
Interventions	Treatment group 1 (SRL/MMF) SRL: doses not reported MMF: doses not reported Treatment group 2 (CSA/MMF) CSA: doses not reported MMF: doses not reported Co‐interventions IL2 Steroids
Outcomes	GFR
Notes	Comparison: TOR‐1 versus CNI Abstract only available
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Said to be a RCT but no details provided.
Allocation concealment (selection bias)	Unclear risk	Said to be a RCT but no details provided
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open‐label study
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement ‐ abstract only
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Insufficient information to permit judgement ‐ abstract only
Selective reporting (reporting bias)	Unclear risk	Insufficient information to permit judgement ‐ abstract only
Other bias	Unclear risk	Insufficient information to permit judgement ‐ abstract only